Clinical trial · Observational
STHLM3 AS NorDCaP - a Followup Study of Men on Active Surveillance of Prostate Cancer
NCT04627948CI-TRIAL-00084914NorDCaP AScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the STHLM3 AS NorDCaP study is to evaluate the Stockholm3 test in an active surveillance cohort to predict upgrading on rebiopsy. The study follows a paired design, evaluating our proposed protocol for follow up men on active surveillance with Stockholm3 versus the standard protocol according to national guidelines with PSA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stockholm3 test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Validate if the Stockholm3 test can be used in an AS cohort to predict upgrading
- timeFrame
- Through study completion, an average of 1 year
- description
- Number of ISUP ≥ 2 prostate cancer
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Men diagnosed with low-risk PC and currently on AS and planned for follow-up with systematic and/or fusion biopsies as following standard of care. Exclusion Criteria: * History of treatment for prostate cancer; surgery, radiation, chemotherapy or hormonal treatment. * Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
References
Publications (1)
- DERIVEDGiudici N, Scuderi S, Palsdottir T, Nordstrom T, Eklund M, Jensby EF, Borre M, Pedersen BG, Gronberg H, Sorensen KD, Kjosavik SR, Lantz A. STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance. BJU Int. 2026 Sep;138(3):471-479. doi: 10.1111/bju.70366. Epub 2026 Jul 1. PMID 42383465